抄録
Hypercholesterolemia is associated with an increased incidence of vascular complications, and Lipoprotein (a) (Lp (a)) is known to appear in high levels in patients with ischemic heart disease. Recently, nicotinic acid was reported as a drug for reducing the serum levels of Lp (a). In order to assess the actual degree of activation of the coagulation and fibrinolytic systems in patients with high levels of Lp (a).
We investigated the effects of niceritrol on plasma lipid, Lp (a) and the molecular markers of the coagulation system. Niceritrol (750-1, 500mg/day) was administered to 50 patients (thirty-two women and 18 men, aged 38-85 years) suffering from hypercholesterolemia with a plasma concentration of total lipoprotein (a) greater than 20mg/dl. The meann concentration of total cholesterol and lipoprotein. (a) were significantly decreased after treatment. At the same time, TAT also significantly decreased. This study suggested that niceritrol may prevent a hypercoagulable state by improving the high levels of Lp (a).
